Hemophilia A
Hemophilia A is a genetic bleeding disorder caused by a deficiency of clotting factor VIII, leading to prolonged bleeding after injury or surgery and spontaneous bleeding episodes.
Hemophilia A: Long-Term Follow-Up of BMN 270
We are investigating the long-term safety and effects of a gene therapy for severe hemophilia A in individuals who participated in a previous study. This includes looking at their quality of life and the need for additional treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you currently enrolled in a hemophilia treatment study or have you completed one of the specified studies in the last 4 months?
- Are you able to give signed consent for participation in the study?
- Do you consider yourself to be in good health without any serious medical conditions?
- Are you currently taking any hemophilia medications?
- Are you currently committed to an institution by judicial or administrative order?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
Cardiovascular Diseases
Heverlee, Belgium
Centre Hospitalier Universitaire De Lille
Institut Cœur Poumon - Hemostase Clinique
Loos, France
Centre Hospitalier Regional De Marseille
Hôpital de La Timone - Hématologie, immunologie et oncologie pédiatrique
Marseille, France
Sponsor: Biomarin Pharmaceutical Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.